All are true about ranolazine except
|A||It causes hypotension|
|B||It is recommended as first line treatment for angina|
|C||It improves glycemic control|
|D||It is not indicated for acute attack of angina|
a. Ranolazine is the first new antianginal drug approved as first-line use for chronic angina.
b. It decreases the late sodium current and thereby decreases intracellular calcium overload.
c. Ranolazine has no effect on heart rate and blood pressure
d. Because it can cause QT prolongation,
e. It also decreases occurrence of atrial fibrillation and results in a small decrease in HbA1C.
f. It is contraindicated in patients with significant liver and kidney disease.
g. Ranolazine is not to be used for treatment of acute anginal episodes